Mesoblast (OTCMKTS:MEOBF) Shares Up 2.6% – Should You Buy?
by Tristan Rich · The Markets DailyMesoblast Limited (OTCMKTS:MEOBF – Get Free Report) rose 2.6% on Wednesday . The company traded as high as $1.59 and last traded at $1.59. Approximately 500 shares traded hands during mid-day trading, a decline of 44% from the average daily volume of 900 shares. The stock had previously closed at $1.55.
Mesoblast Trading Up 2.6%
The business has a 50-day moving average of $1.58 and a 200-day moving average of $1.58.
About Mesoblast
Mesoblast Limited (OTCMKTS:MEOBF) is a global leader in regenerative medicine focused on the development and commercialization of innovative allogeneic cell therapies. The company’s proprietary platform harnesses mesenchymal lineage adult stem cells to address a range of inflammatory and immunological conditions. Mesoblast’s pipeline includes multiple late-stage and marketed products that target serious diseases with high unmet medical needs.
The company’s lead product, remestemcel-L (Ryvicor/Ryoncil), is under development for the treatment of steroid-refractory acute graft versus host disease in pediatric patients and has received conditional approval for certain indications in Japan.